Compare · AGL vs NIVF
AGL vs NIVF
Side-by-side comparison of agilon health inc. (AGL) and NewGenIvf Group Limited (NIVF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and NIVF operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- AGL is the larger of the two at $2.05B, about 418.3x NIVF ($4.9M).
- Over the past year, AGL is up 123.2% and NIVF is down 99.7% - AGL leads by 223.0 points.
- NIVF has been more active in the news (7 items in the past 4 weeks vs 2 for AGL).
- AGL has more recent analyst coverage (25 ratings vs 0 for NIVF).
PerformanceAGL+126.30%NIVF-99.74%
2025-07-16+0.00%2026-07-14
- Company
- agilon health inc.
- NewGenIvf Group Limited
- Price
- $122.50+5.67%
- $1.38-1.43%
- Market cap
- $2.05B
- $4.9M
- 1M return
- +5.89%
- -15.28%
- 1Y return
- +123.25%
- -99.74%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 7
- Recent ratings
- 25
- 0
AGL
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Latest AGL
- agilon health Sets Date to Report Second Quarter 2026 Financial Results
- Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 2,311 shares, decreasing direct ownership by 2% to 138,031 units (SEC Form 4) to satisfy tax liability
- agilon health to Participate in Upcoming Conferences
- Chief Legal Officer Zamore Denise covered exercise/tax liability with 485 shares, decreasing direct ownership by 0.73% to 66,112 units (SEC Form 4) (tax liability)
- Director Wulf John William was granted 2,133 shares, increasing direct ownership by 15% to 16,765 units (SEC Form 4)
- Director Williams Ronald A was granted 2,133 shares, increasing direct ownership by 1% to 149,141 units (SEC Form 4)
- Director Mcloughlin Karen was granted 2,133 shares, increasing direct ownership by 35% to 8,207 units (SEC Form 4)
- Director Mckenzie Diana was granted 2,133 shares, increasing direct ownership by 39% to 7,633 units (SEC Form 4)
- Director Mansukani Sharad was granted 2,133 shares, increasing direct ownership by 4% to 56,242 units (SEC Form 4)
- Director Battaglia Silvana was granted 2,133 shares, increasing direct ownership by 37% to 7,926 units (SEC Form 4)
Latest NIVF
- SEC Form 4 filed by Director Siu Wing Fung Alfred
- SEC Form 4 filed by Director Fong Hei Yue Tina
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen’s Advanced Cytometry Platform Poised for Major UAE/GCC Expansion with Big Four Valuation of US$19 Million
- SEC Form 6-K filed by NewGenIvf Group Limited
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested
- SEC Form 6-K filed by NewGenIvf Group Limited